Work

Clinical impact of a precision oncology review workflow for actionable genomic findings.

Year: 2026
Type: conference-abstract
Abstract: 714 Background: Comprehensive Next-Generation Sequencing (NGS) is integral to guideline-directed care to identify actionable molecular mutations and inform treatment selection in advanced malignancies. As data on mutations continue to expand, effective interpretation and clinical follow-up have become increasingly complex. At the University of Illinois Cancer Center, our Precision Oncology Program (POP) systematically reviews NGS reports to identify actionable findings, potential care gaps, and case referrals for formal review at the Precision Oncology Tumor Board (POTB). We evaluated the impact of this manual review workflow. Methods: We conducted a retrospective quality improvement analysis of NGS reports reviewed through the POP workflow between June 2025 and June 2026. Actionable mutations were defined as mutations identified through the Tempus Hub that were concordant with NCCN guideline-recommended therapy for their respective cancer type. POP intervention was defined as a genomic finding identified through POPreview that prompted physician notification, recommended additional testing, referred to POTB, or led to consideration of a guideline-concordant treatment modification. Demographic and clinical data were collected through chart review (Table). Sequencing data included both tissue and liquid samples. Results: A total of 584 NGS reports were reviewed. Of 108 patients with actionable alterations, 48 (44%) required POP intervention. Overall, POP intervention occurred in 8% of all reviewed reports. In patients with actionable mutations, 77% had stage IV disease. The most common malignancies were lung (33%), genitourinary (GU) (24%), gastrointestinal (GI) (22%), and breast (11%). Of patients with stage IV disease, 83% had lung cancer, 81% GU cancer, 67% GI cancer, and 92% breast cancer. When stratified by tumor type, POP intervention was required in 25% of lung, 50% GU, 50% GI, and 50% breast cancer cases. Conclusions: Manual review of NGS reports identified actionable genomic alterations in 18% of patients, of which 44% prompted POP intervention. These results suggest that a substantial proportion of molecular findings may benefit from additional review. As the volume and complexity of genomic data expand, structured review workflows may serve as an important quality improvement strategy to facilitate timely recognition of actionable findings in treatment decision-making. Patient demographics from June 2025-June 2026. Age Total (n=108) Age>64 63 (58%) Age≤64 45 (42%) Sex Male 60 (56%) Female 48 (44%) Race Black 50 (46%) White 23 (21%) Latino/a 23 (21%) Asian 12 (11%) Ethnicity Hispanic 24 (22%) Not Hispanic 84 (78%) Insurance Medicare 49 (45%) Medicaid 31 (29%) Commercial 25 (23%) Uninsured 3 (3%) Cancer Type Lung 36 (33%) Genitourinary 26 (24%) Gastrointestinal 24 (22%) Breast 12 (11%) Head/Neck 4 (4%) Skin 3 (3%)
Language: English
Subfield: Cancer Research
Open Access status: bronze
OpenAlex ID: W7221589915
Cites:
Cited by:
Related to: 10